Loading viewer...
conference
Format: PDF conference
Phase II trial evaluating the safety and efficacy of pembrolizumab combined with eftilagimod alpha (LAG-3 agonist) and radiotherapy as neoadjuvant treatment for high-grade soft tissue sarcomas. The study assesses tumor pathologic response, measured by hyalinization, and explores changes in the tumor microenvironment and immune infiltrates. Funded by the Medical Research Agency in Poland.
conference
24 Pages
Eramet
Emerald Holding Inc Investor Presentation 2022
conferenceconference
18 Pages
Emerald Holding, Inc.
Advanced Enzyme Technologies Motilal Oswal Biotech Medtech Day 2021
conferenceconference
11 Pages
Advanced Enzyme Technologies Limited